DE60128208T2 - Verfahren zum Behandeln von Krebs mit Anti-Neurotrophin-Mitteln - Google Patents
Verfahren zum Behandeln von Krebs mit Anti-Neurotrophin-Mitteln Download PDFInfo
- Publication number
- DE60128208T2 DE60128208T2 DE60128208T DE60128208T DE60128208T2 DE 60128208 T2 DE60128208 T2 DE 60128208T2 DE 60128208 T DE60128208 T DE 60128208T DE 60128208 T DE60128208 T DE 60128208T DE 60128208 T2 DE60128208 T2 DE 60128208T2
- Authority
- DE
- Germany
- Prior art keywords
- neurotrophin
- day
- antibody
- antibodies
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract description 197
- 201000011510 cancer Diseases 0.000 title abstract description 29
- 238000000034 method Methods 0.000 title abstract description 13
- 108010025020 Nerve Growth Factor Proteins 0.000 claims abstract description 137
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims abstract description 27
- 201000002528 pancreatic cancer Diseases 0.000 claims abstract description 24
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 20
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 20
- 102000015336 Nerve Growth Factor Human genes 0.000 claims abstract description 18
- 108090000742 Neurotrophin 3 Proteins 0.000 claims abstract description 17
- 208000008443 pancreatic carcinoma Diseases 0.000 claims abstract description 17
- 210000002307 prostate Anatomy 0.000 claims abstract description 17
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims abstract description 16
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims abstract description 15
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims abstract description 15
- 241000124008 Mammalia Species 0.000 claims abstract description 12
- 102100033857 Neurotrophin-4 Human genes 0.000 claims abstract description 11
- 239000012634 fragment Substances 0.000 claims abstract description 11
- 101000996663 Homo sapiens Neurotrophin-4 Proteins 0.000 claims abstract description 10
- 102100029268 Neurotrophin-3 Human genes 0.000 claims abstract 2
- 241000282414 Homo sapiens Species 0.000 claims description 28
- 230000012010 growth Effects 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 17
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 102000007072 Nerve Growth Factors Human genes 0.000 abstract description 120
- 239000003795 chemical substances by application Substances 0.000 abstract description 10
- 230000000692 anti-sense effect Effects 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 description 45
- 241000699666 Mus <mouse, genus> Species 0.000 description 36
- 230000000694 effects Effects 0.000 description 34
- 210000004027 cell Anatomy 0.000 description 32
- 238000002474 experimental method Methods 0.000 description 30
- 241000283973 Oryctolagus cuniculus Species 0.000 description 29
- 238000002347 injection Methods 0.000 description 26
- 239000007924 injection Substances 0.000 description 26
- 241000699660 Mus musculus Species 0.000 description 23
- 238000011580 nude mouse model Methods 0.000 description 23
- 241000699670 Mus sp. Species 0.000 description 19
- UIARLYUEJFELEN-LROUJFHJSA-N LSM-1231 Chemical compound C12=C3N4C5=CC=CC=C5C3=C3C(=O)NCC3=C2C2=CC=CC=C2N1[C@]1(C)[C@](CO)(O)C[C@H]4O1 UIARLYUEJFELEN-LROUJFHJSA-N 0.000 description 18
- 102000005962 receptors Human genes 0.000 description 16
- 108020003175 receptors Proteins 0.000 description 16
- 102000004230 Neurotrophin 3 Human genes 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 15
- 229940053128 nerve growth factor Drugs 0.000 description 15
- 229940032018 neurotrophin 3 Drugs 0.000 description 15
- 230000004614 tumor growth Effects 0.000 description 15
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
- 239000003981 vehicle Substances 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 13
- 230000002601 intratumoral effect Effects 0.000 description 13
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 10
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 10
- NMMGUHANGUWNBN-OGLOGDKOSA-N cep-751 Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1C[C@](OC)(CO)[C@]4(C)O1 NMMGUHANGUWNBN-OGLOGDKOSA-N 0.000 description 10
- 230000037396 body weight Effects 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 101100222854 Bacillus subtilis (strain 168) czcO gene Proteins 0.000 description 8
- 101100127166 Escherichia coli (strain K12) kefB gene Proteins 0.000 description 8
- 101100537961 Methanosarcina mazei (strain ATCC BAA-159 / DSM 3647 / Goe1 / Go1 / JCM 11833 / OCM 88) trkA2 gene Proteins 0.000 description 8
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 101150025395 trkA gene Proteins 0.000 description 8
- 101150113435 trkA1 gene Proteins 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 208000023958 prostate neoplasm Diseases 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 102000047459 trkC Receptor Human genes 0.000 description 6
- 108010064892 trkC Receptor Proteins 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 210000001541 thymus gland Anatomy 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 102100026879 Interleukin-2 receptor subunit beta Human genes 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 230000035578 autophosphorylation Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
- 108090000099 Neurotrophin-4 Proteins 0.000 description 3
- 108090000095 Neurotrophin-6 Proteins 0.000 description 3
- 101710111575 Neurotrophin-7 Proteins 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 208000035269 cancer or benign tumor Diseases 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 229940069328 povidone Drugs 0.000 description 3
- 201000001514 prostate carcinoma Diseases 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 102100023460 Choline O-acetyltransferase Human genes 0.000 description 2
- 108010058699 Choline O-acetyltransferase Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 102000003683 Neurotrophin-4 Human genes 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 208000006994 Precancerous Conditions Diseases 0.000 description 2
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000003391 densitometric scan Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 108020004084 membrane receptors Proteins 0.000 description 2
- 102000006240 membrane receptors Human genes 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 210000004129 prosencephalon Anatomy 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 239000003104 tissue culture media Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DAXJNUBSBFUTRP-RTQNCGMRSA-N (8r,9s,10r,13s,14s)-6-(hydroxymethyl)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-dione Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(CO)C2=C1 DAXJNUBSBFUTRP-RTQNCGMRSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- CVOFKRWYWCSDMA-UHFFFAOYSA-N 2-chloro-n-(2,6-diethylphenyl)-n-(methoxymethyl)acetamide;2,6-dinitro-n,n-dipropyl-4-(trifluoromethyl)aniline Chemical compound CCC1=CC=CC(CC)=C1N(COC)C(=O)CCl.CCCN(CCC)C1=C([N+]([O-])=O)C=C(C(F)(F)F)C=C1[N+]([O-])=O CVOFKRWYWCSDMA-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108010082830 CEP 2563 Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- PBEVPBFDKPJIOM-HQKLUXGTSA-N Cl.Cl.C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@](OC)(COC(=O)CCNC(=O)[C@@H](N)CCCCN)[C@]4(C)O1 Chemical compound Cl.Cl.C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@](OC)(COC(=O)CCNC(=O)[C@@H](N)CCCCN)[C@]4(C)O1 PBEVPBFDKPJIOM-HQKLUXGTSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102100020948 Growth hormone receptor Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 1
- 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 1
- 101150111783 NTRK1 gene Proteins 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 108010068542 Somatotropin Receptors Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 102000054751 human RUNX1T1 Human genes 0.000 description 1
- 229940077456 human brain-derived neurotrophic factor Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- VVVPGLRKXQSQSZ-UHFFFAOYSA-N indolo[3,2-c]carbazole Chemical class C1=CC=CC2=NC3=C4C5=CC=CC=C5N=C4C=CC3=C21 VVVPGLRKXQSQSZ-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 229940097998 neurotrophin 4 Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 201000003733 ovarian melanoma Diseases 0.000 description 1
- 229940127013 pan-TRK inhibitor Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000371 poly(diallyldimethylammonium chloride) polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- VUYXVWGKCKTUMF-UHFFFAOYSA-N tetratriacontaethylene glycol monomethyl ether Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO VUYXVWGKCKTUMF-UHFFFAOYSA-N 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18594300P | 2000-02-29 | 2000-02-29 | |
| US185943P | 2000-02-29 | ||
| US793850 | 2001-02-27 | ||
| US09/793,850 US6548062B2 (en) | 2000-02-29 | 2001-02-27 | Method of treating cancer with anti-neurotrophin agents |
| PCT/US2001/006266 WO2001064247A2 (en) | 2000-02-29 | 2001-02-28 | Method of treating cancer with anti-neurotrophin agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60128208D1 DE60128208D1 (de) | 2007-06-14 |
| DE60128208T2 true DE60128208T2 (de) | 2008-01-10 |
Family
ID=26881613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60128208T Expired - Lifetime DE60128208T2 (de) | 2000-02-29 | 2001-02-28 | Verfahren zum Behandeln von Krebs mit Anti-Neurotrophin-Mitteln |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US6548062B2 (enExample) |
| EP (1) | EP1261372B1 (enExample) |
| JP (1) | JP2003525253A (enExample) |
| CN (1) | CN1227033C (enExample) |
| AT (1) | ATE361100T1 (enExample) |
| AU (2) | AU2001239913B2 (enExample) |
| CA (1) | CA2401604C (enExample) |
| DE (1) | DE60128208T2 (enExample) |
| ES (1) | ES2286110T3 (enExample) |
| HK (1) | HK1049961B (enExample) |
| MX (1) | MXPA02008465A (enExample) |
| NZ (1) | NZ521165A (enExample) |
| WO (1) | WO2001064247A2 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100081197A1 (en) * | 1997-08-14 | 2010-04-01 | Sylvie Roux | In vivo modulation of neuronal transport |
| JP3773733B2 (ja) * | 2000-01-13 | 2006-05-10 | 松下電器産業株式会社 | 陰極線管 |
| FR2807660A1 (fr) * | 2000-04-13 | 2001-10-19 | Warner Lambert Co | Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques |
| CN1684708A (zh) * | 2001-05-30 | 2005-10-19 | 基因技术股份有限公司 | 抗ngf抗体用于治疗各种疾病 |
| US20060147450A1 (en) * | 2002-10-04 | 2006-07-06 | Shelton David L | Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists |
| UA80447C2 (en) | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
| WO2005000194A2 (en) | 2002-10-08 | 2005-01-06 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same |
| JP4584713B2 (ja) * | 2002-10-08 | 2010-11-24 | ライナット ニューロサイエンス コーポレイション | 神経成長因子アンタゴニストを投与することによって術後疼痛を処置するための方法および神経成長因子アンタゴニストを含有する組成物 |
| FR2846426B1 (fr) * | 2002-10-28 | 2004-12-10 | Bio Merieux | Procede de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie |
| US9498530B2 (en) | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
| CN101014364B (zh) * | 2002-12-24 | 2012-01-18 | 里纳特神经系统学公司 | 抗ngf抗体及其使用方法 |
| US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
| PL379983A1 (pl) * | 2003-02-19 | 2006-11-27 | Rinat Neuroscience Corp. | Sposoby leczenia bólu polegające na podaniu antagonisty czynnika wzrostu nerwów i niesteroidowego leku przeciwzapalnego oraz zawierające je kompozycje |
| US20050043215A1 (en) * | 2003-02-19 | 2005-02-24 | Tamara Minko | Complex drug delivery composition and method for treating cancer |
| EA013614B1 (ru) * | 2003-07-15 | 2010-06-30 | Амджен Инк. | Изолированное антитело к фактору роста нервов (ngf) и способы его применения |
| ES2616337T3 (es) * | 2003-12-12 | 2017-06-12 | Government Of The United States Of America, As Repr. By The Secr. Of The Dept. Of Health And Human Services And His Successors | Un epítopo de linfocito T citotóxico humano y su epítopo agonista del número no variable de secuencias de repetición en tándem de MUC-1 |
| ITRM20030601A1 (it) * | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
| EP3372614B1 (en) * | 2004-04-07 | 2022-06-08 | Rinat Neuroscience Corp. | Methods for treating bone cancer pain by administering a nerve growth factor antagonist |
| ME00226B (me) | 2004-07-15 | 2011-02-10 | Medarex Llc | Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade |
| US20090196850A1 (en) | 2005-01-06 | 2009-08-06 | Novo Nordisk A/S | Anti-Kir Combination Treatments and Methods |
| NZ556157A (en) | 2005-01-24 | 2009-09-25 | Elan Pharma Int Ltd | Specific binding members for NGF |
| ITRM20050290A1 (it) * | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
| FR2896881B1 (fr) * | 2006-01-31 | 2008-04-18 | Biomerieux Sa | Procede de dosage du prongf pour le diagnostic in vitro du cancer du sein et utilisation du prongf en therapie |
| US8309088B2 (en) | 2007-08-10 | 2012-11-13 | Regeneron Pharmaceuticals, Inc. | Method of treating osteoarthritis with an antibody to NGF |
| RS53661B1 (sr) | 2007-08-10 | 2015-04-30 | Regeneron Pharmaceuticals, Inc. | Humana antitela visokog afiniteta prema humanom nervnom faktoru rasta |
| US20110229485A1 (en) * | 2008-05-21 | 2011-09-22 | Centre National De La Recherche Scientfique (Cnrs) | Inhibition of the nt-3:trkc bound and its application to the treatment of cancer such as neuroblastoma |
| WO2009150623A1 (en) | 2008-06-13 | 2009-12-17 | Pfizer Inc | Treatment of chronic prostatitis |
| JP2012515158A (ja) | 2009-01-12 | 2012-07-05 | 武田薬品工業株式会社 | 癌の予防・治療剤 |
| EA201190115A1 (ru) | 2009-01-24 | 2012-02-28 | ФИТОФАРМ ПиЭлСи | Лечение расстройств, опосредованных нейротрофическим фактором |
| US8435523B2 (en) * | 2009-05-04 | 2013-05-07 | Abbott Research B.V. | Antibodies against nerve growth factor (NGF) with enhanced in vivo stability |
| EP2547365A1 (en) | 2010-03-17 | 2013-01-23 | Abbott Research B.V. | Anti-nerve growth factor (ngf) antibody compositions |
| CA2808577C (en) | 2010-08-19 | 2018-09-25 | Abbott Laboratories | Anti-ngf antibodies and their use |
| JP6105838B2 (ja) * | 2010-08-24 | 2017-03-29 | 国立大学法人 岡山大学 | 疼痛の治療剤 |
| US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
| WO2012075340A2 (en) | 2010-12-01 | 2012-06-07 | Alderbio Holdings Llc | Anti-ngf compositions and use thereof |
| US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
| US8926978B2 (en) | 2011-10-25 | 2015-01-06 | Anaptysbio, Inc. | Antibodies directed against nerve growth factor (NGF) |
| AU2013271564A1 (en) | 2012-06-06 | 2014-12-04 | Zoetis Services Llc | Caninized anti-NGF antibodies and methods thereof |
| EP2859019B1 (en) | 2012-06-08 | 2018-02-21 | Glenmark Pharmaceuticals S.A. | Humanized anti-trka antibodies with amino acid substitutions |
| TWI703158B (zh) * | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
| CA3093772C (en) | 2018-03-12 | 2024-04-16 | Zoetis Services Llc | Anti-ngf antibodies and methods thereof |
| MX2024007088A (es) | 2021-12-16 | 2024-08-22 | Intervet Int Bv | Anticuerpos caninizados contra el ngf humano. |
| EP4514998A1 (en) | 2022-04-27 | 2025-03-05 | Regeneron Pharmaceuticals, Inc. | Treatment of arthropathy based upon stratification of osteoarthritis polygenic risk score |
| US20240310383A1 (en) | 2023-03-17 | 2024-09-19 | Regeneron Pharmaceuticals, Inc. | Proteomic Risk Score For Osteoarthritis (OA) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1073264A (zh) | 1991-11-12 | 1993-06-16 | 里珍纳龙药品有限公司 | 基于组织的特定的nt-3表达与受体结合的治疗和诊断方法 |
| AU5102493A (en) | 1992-09-11 | 1994-04-12 | Cephalon, Inc. | A method for the detection and treatment of prostate disease |
| US5844092A (en) * | 1994-03-18 | 1998-12-01 | Genentech, Inc. | Human TRK receptors and neurotrophic factor inhibitors |
| EP0753013A1 (en) * | 1994-03-29 | 1997-01-15 | Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. | Neurotrophin-6: a new member of the neurotrophin family |
-
2001
- 2001-02-27 US US09/793,850 patent/US6548062B2/en not_active Expired - Lifetime
- 2001-02-28 CA CA2401604A patent/CA2401604C/en not_active Expired - Fee Related
- 2001-02-28 CN CNB018058108A patent/CN1227033C/zh not_active Expired - Fee Related
- 2001-02-28 AU AU2001239913A patent/AU2001239913B2/en not_active Ceased
- 2001-02-28 AT AT01914537T patent/ATE361100T1/de not_active IP Right Cessation
- 2001-02-28 MX MXPA02008465A patent/MXPA02008465A/es active IP Right Grant
- 2001-02-28 AU AU3991301A patent/AU3991301A/xx active Pending
- 2001-02-28 NZ NZ521165A patent/NZ521165A/en not_active IP Right Cessation
- 2001-02-28 JP JP2001563144A patent/JP2003525253A/ja active Pending
- 2001-02-28 DE DE60128208T patent/DE60128208T2/de not_active Expired - Lifetime
- 2001-02-28 HK HK03102054.6A patent/HK1049961B/en not_active IP Right Cessation
- 2001-02-28 EP EP01914537A patent/EP1261372B1/en not_active Expired - Lifetime
- 2001-02-28 WO PCT/US2001/006266 patent/WO2001064247A2/en not_active Ceased
- 2001-02-28 ES ES01914537T patent/ES2286110T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| AU2001239913B2 (en) | 2005-12-08 |
| HK1049961A1 (en) | 2003-06-06 |
| HK1049961B (en) | 2007-09-14 |
| ES2286110T3 (es) | 2007-12-01 |
| CA2401604A1 (en) | 2001-09-07 |
| MXPA02008465A (es) | 2003-03-10 |
| CA2401604C (en) | 2011-05-24 |
| WO2001064247A3 (en) | 2002-02-14 |
| EP1261372A2 (en) | 2002-12-04 |
| JP2003525253A (ja) | 2003-08-26 |
| NZ521165A (en) | 2004-08-27 |
| US20010046959A1 (en) | 2001-11-29 |
| EP1261372B1 (en) | 2007-05-02 |
| CN1227033C (zh) | 2005-11-16 |
| ATE361100T1 (de) | 2007-05-15 |
| DE60128208D1 (de) | 2007-06-14 |
| CN1420785A (zh) | 2003-05-28 |
| US6548062B2 (en) | 2003-04-15 |
| AU3991301A (en) | 2001-09-12 |
| WO2001064247A2 (en) | 2001-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60128208T2 (de) | Verfahren zum Behandeln von Krebs mit Anti-Neurotrophin-Mitteln | |
| DE69014474T2 (de) | Antikörper gegen TNF-Bindungsprotein I und deren F(ab)-Fragmente. | |
| DE69926536T2 (de) | Antagonisten von vaskular-endothelialen zellwachstumsfaktoren und ihre anwendung | |
| DE69532767T2 (de) | Peptid umfassend eine Sequenz aus einer Fusionsverbindungsstelle in einem mutierten EGF-Rezeptor vom Typ III | |
| DE60038252T2 (de) | Menschlicher Antikörper gegen Gangliosid GD3 für die Transplantationskomplentarität bestimmende Region und Derivate des Antikörpers gegen das Gangliosid GD3 | |
| JP4584713B2 (ja) | 神経成長因子アンタゴニストを投与することによって術後疼痛を処置するための方法および神経成長因子アンタゴニストを含有する組成物 | |
| DE69737397T2 (de) | Verwendung von mif-antagonisten zur krebstherapie | |
| DE60009484T3 (de) | Als ngf-antagonisten wirkende monoklonale antiköper und deren synthetische und biotechnologische derivate | |
| AU2001239913A1 (en) | Method of treating cancer with anti-neurotrophin agents | |
| JP2006504744A5 (enExample) | ||
| KR20060026860A (ko) | 신경근 장애의 치료를 위한, 코르티코스테로이드와 조합된미오스타틴 (ｇｄｆ８) 저해제의 용도 | |
| DE69034087T2 (de) | Antiidiotypischer Antikörper, der ein Immunantwort gegen ein Glykosphingolipid induziert und seine Verwendung | |
| DE60316106T2 (de) | Gemeinsamer lymphatischer endothel- und gefässendothel-rezeptor-1 (clever-1) und seine verwendung | |
| DE69110060T2 (de) | In der humantherapie nützliche substanzen peptidischer natur. | |
| DE69229394T2 (de) | Zusammensetzungen und methoden zur behandlung von kleinzell und nicht-kleinzell lungenkrebsen | |
| DE10353593A1 (de) | Leptinantagonist und Verfahren zur quantitativen Messung von Leptin | |
| DE69837322T2 (de) | Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln | |
| DE60111515T2 (de) | Kombinationstherapie mit keratinozyten-wachstumfaktor und ein epidermis-wachstumfaktor inhibitor | |
| EP1236740A1 (de) | Vakzine gegen Krebserkrankungen, die mit dem HER-2/neu Onkogen assoziiert sind | |
| DE69835016T2 (de) | Verwendung von midkin oder von anti-midkin antikörper | |
| DE212011100195U9 (de) | Antikörper, der das Tumorwachstum stoppt oder verzögert (Varianten) | |
| EP2450055B1 (en) | Method for suppressing renal tumor growth by blocking fibroblast growth factor receptor | |
| DE69331942T2 (de) | Verwendung und herstellung eines metastaseninhibitors bzw. eines zelladhäsionsinhibitors enthaltend einen antikörper | |
| DE69937057T2 (de) | Verwendung von basiliximab zur behandlung von rheumatoider arthritis und hauterkrankungen | |
| US20250074991A1 (en) | Methods of treating nausea and vomiting disorders using anti-gfral antibodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |